University of Geneva
Geneva, 1211, Switzerland
NCT Number: NCT02631980
Hepcifer Trial is designed to assess the value of iv iron administration immediately after liver surgery and consequences of inflammation on iron balance. Fifty patients will be randomized in two treatment groups. Patients will be assigned to receive either iv iron or placebo immediately after liver resection surgery. Biological inflammation parameters, hemoglobin, serum iron and hepcidin levels will be assessed prior to surgery and at day 1, 3, 7, 15 and 30 after surgery.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Geneva, 1211, Switzerland
The iron homeostasis is now well known. Indeed, the discovery of hepcidin, a protein synthesized by the liver, has provided a better understanding of iron metabolism and the resulting anemia disruption of this homeostasis.
Although morbidity decreased hepatic surgery remains a major surgery as by surgical difficulty by support intra- and postoperatively.
A preliminary study, the investigators found that patients had preoperative anemia (oncological context) increased postoperatively, increasing the morbidity.
Few clinical studies on hepcidin and anemia were carried out, because of the difficulty of metering (mass spectrometry) as well as its cost.
In this clinical trial, the investigators plan to assess the value of iv iron administration versus iv placebo treatment immediately after liver surgery and consequences of inflammation on iron balance. In addition, an evaluation of the well being of patients will be performed postoperatively to measure the functional and psychological impact of anemia.
This is a monocentric, randomized, double blinded and placebo controlled trial. Iron iv injection will be administered postoperatively. Hematology assessments, biological iron deficiency, inflammation and coagulation will be realized pre and postoperatively. Hepcidin is assayed by an ELISA method.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intravenous iron 15 mg/kg (max 1000 mg) in 250 ml 0.9% saline
Other names: Ferinject
Intravenous 0.9% saline (250 ml)
Other names: Placebo
Time frame: Postoperative Day 7
Blood sample at postoperative Day 7
Time frame: Through study completion, an average of 1 year
Time frame: Postoperative Day 30
Questionnaire
University Hospital, Geneva
Other
Hepcidin Overexpression After Hepatectomy : Does Iron Supplementation Make Sense ?
Acronym: HepciFer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05750654
Anemia, Hematologic Diseases
Houston, Texas, United States
View Trial DetailsNCT03369210
Anemia, Hematologic Diseases
Aachen, Germany
View Trial DetailsNCT01572506
Anemia, Hematologic Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT07708025
Anemia, Cardiovascular Diseases
Porto, Portugal
View Trial Details